Determination of Asymmetric and Symmetric Dimethylarginine in Serum from Patients with Chronic Kidney Disease: UPLC-MS/MS Versus ELISA

Overview

Journal Toxins (Basel)

Publisher MDPI

Specialty Toxicology

Date 2016 May 18

PMID 27187471

Citations 18

Authors

Jente Boelaert

Eva Schepers

Griet Glorieux

Sunny Eloot

Raymond Vanholder

Frederic Lynen

Affiliations

Soon will be listed here.

Abstract

Asymmetric dimethylarginine (ADMA), an endogenous inhibitor of nitric oxide (NO) synthesis, and its structural isomer symmetric dimethylarginine (SDMA) are uremic toxins accumulating in chronic kidney disease (CKD) patients. The objective of this study was to develop and validate a robust UPLC-MS/MS method for the simultaneous determination of ADMA and SDMA in human serum. Chromatographic separation after butyl ester derivatization was achieved on an Acquity UPLC BEH C18 column, followed by tandem mass spectrometric detection. After validation, the applicability of the method was evaluated by the analysis of serum samples from 10 healthy controls and 77 CKD patients on hemodialysis (CKD5HD). Both ADMA (0.84 ± 0.19 µM vs. 0.52 ± 0.07 µM) and SDMA concentrations (2.06 ± 0.82 µM vs. 0.59 ± 0.13 µM) were significantly (p < 0.001) elevated in CKD5HD patients compared to healthy controls. In general, low degrees of protein binding were found for both ADMA and SDMA. In addition, an established commercially available ELISA kit was utilized on the same samples (n = 87) to compare values obtained both with ELISA and UPLC-MS/MS. Regression analysis between these two methods was significant (p < 0.0001) but moderate for both ADMA (R = 0.78) and SDMA (R = 0.72).

Citing Articles

Comparison of two methods for dimethylarginines quantification.

Sudova V, Prokop P, Trefil L, Racek J, Rajdl D Pract Lab Med. 2024; 39:e00359.

PMID: 38313812 PMC: 10831080. DOI: 10.1016/j.plabm.2024.e00359.

Serum symmetric dimethylarginine in older dogs: Reference interval and comparison of a gold standard method with the ELISA.

Marynissen S, Junius G, Van den Steen E, Patteet L, Duchateau L, Croubels S J Vet Intern Med. 2024; 38(2):960-970.

PMID: 38240346 PMC: 10937498. DOI: 10.1111/jvim.16981.

Comparison of BTP, NGAL, KIM-1, & ADMA biomarkers in CKD and non-CKD subjects.

Bansal A, Nigoskar S, Thalquotra M Int J Biochem Mol Biol. 2023; 14(3):32-39.

PMID: 37456909 PMC: 10349297.

Asymmetric and Symmetric Dimethylarginines as Renal Function Parameters in Paediatric Kidney Diseases: A Literature Review from 2003 to 2022.

Jezierska M, Stefanowicz J Children (Basel). 2022; 9(11).

PMID: 36360396 PMC: 9688657. DOI: 10.3390/children9111668.

Nitric Oxide Synthesis Metabolites-As Potential Markers in Chronic Kidney Disease in Children.

Piechowicz J, Gamian A, Chukwu O, Polak-Jonkisz D Curr Issues Mol Biol. 2022; 44(8):3518-3532.

PMID: 36005138 PMC: 9406431. DOI: 10.3390/cimb44080242.

References

Vishwanathan K, Tackett R, Stewart J, Bartlett M . Determination of arginine and methylated arginines in human plasma by liquid chromatography-tandem mass spectrometry. J Chromatogr B Biomed Sci Appl. 2000; 748(1):157-66. DOI: 10.1016/s0378-4347(00)00399-6. View

Sitar M, Kayacelebi A, Beckmann B, Kielstein J, Tsikas D . Asymmetric dimethylarginine (ADMA) in human blood: effects of extended haemodialysis in the critically ill patient with acute kidney injury, protein binding to human serum albumin and proteolysis by thermolysin. Amino Acids. 2015; 47(9):1983-93. DOI: 10.1007/s00726-015-1991-4. View

Zoccali C, Mallamaci F, Benedetto F, Tripepi G, Malatino L, Cataliotti A . Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study. Lancet. 2002; 358(9299):2113-7. DOI: 10.1016/s0140-6736(01)07217-8. View

Teerlink T, Nijveldt R, de Jong S, van Leeuwen P . Determination of arginine, asymmetric dimethylarginine, and symmetric dimethylarginine in human plasma and other biological samples by high-performance liquid chromatography. Anal Biochem. 2002; 303(2):131-7. DOI: 10.1006/abio.2001.5575. View

Marra M, Bonfigli A, Testa R, Testa I, Gambini A, Coppa G . High-performance liquid chromatographic assay of asymmetric dimethylarginine, symmetric dimethylarginine, and arginine in human plasma by derivatization with naphthalene-2,3-dicarboxaldehyde. Anal Biochem. 2003; 318(1):13-7. DOI: 10.1016/s0003-2697(03)00157-x. View

Fleck C, Schweitzer F, Karge E, Busch M, Stein G . Serum concentrations of asymmetric (ADMA) and symmetric (SDMA) dimethylarginine in patients with chronic kidney diseases. Clin Chim Acta. 2003; 336(1-2):1-12. DOI: 10.1016/s0009-8981(03)00338-3. View

Boger R . The emerging role of asymmetric dimethylarginine as a novel cardiovascular risk factor. Cardiovasc Res. 2003; 59(4):824-33. DOI: 10.1016/s0008-6363(03)00500-5. View

Heresztyn T, Worthley M, Horowitz J . Determination of l-arginine and NG, NG - and NG, NG' -dimethyl-L-arginine in plasma by liquid chromatography as AccQ-Fluor fluorescent derivatives. J Chromatogr B Analyt Technol Biomed Life Sci. 2004; 805(2):325-9. DOI: 10.1016/j.jchromb.2004.03.020. View

Albsmeier J, Schwedhelm E, Schulze F, Kastner M, Boger R . Determination of NG,NG-dimethyl-L-arginine, an endogenous NO synthase inhibitor, by gas chromatography-mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2004; 809(1):59-65. DOI: 10.1016/j.jchromb.2004.06.008. View

10.

Pacifici G, Viani A, Rizzo G, Carrai M, Schulz H . Effects of development, aging, and renal and hepatic insufficiency as well as hemodialysis on the plasma concentrations of albumin and alpha 1-acid glycoprotein: implications for binding of drugs. Ther Drug Monit. 1986; 8(3):259-63. DOI: 10.1097/00007691-198609000-00003. View

11.

Kremer J, Wilting J, Janssen L . Drug binding to human alpha-1-acid glycoprotein in health and disease. Pharmacol Rev. 1988; 40(1):1-47. View

12.

Vallance P, Leone A, Calver A, Collier J, Moncada S . Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet. 1992; 339(8793):572-5. DOI: 10.1016/0140-6736(92)90865-z. View

13.

Boger R, Bode-Boger S, Szuba A, Tsao P, Chan J, Tangphao O . Asymmetric dimethylarginine (ADMA): a novel risk factor for endothelial dysfunction: its role in hypercholesterolemia. Circulation. 1998; 98(18):1842-7. DOI: 10.1161/01.cir.98.18.1842. View

14.

Foley R, Parfrey P, Sarnak M . Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis. 1998; 32(5 Suppl 3):S112-9. DOI: 10.1053/ajkd.1998.v32.pm9820470. View

15.

Huang L, Guo F, Liang Y, Li B, Cheng B . Simultaneous determination of L-arginine and its mono- and dimethylated metabolites in human plasma by high-performance liquid chromatography-mass spectrometry. Anal Bioanal Chem. 2004; 380(4):643-9. DOI: 10.1007/s00216-004-2759-y. View

16.

Kielstein J, Boger R, Bode-Boger S, Martens-Lobenhoffer J, Lonnemann G, Frolich J . Low dialysance of asymmetric dimethylarginine (ADMA)--in vivo and in vitro evidence of significant protein binding. Clin Nephrol. 2004; 62(4):295-300. DOI: 10.5414/cnp62295. View

17.

Martens-Lobenhoffer J, Krug O, Bode-Boger S . Determination of arginine and asymmetric dimethylarginine (ADMA) in human plasma by liquid chromatography/mass spectrometry with the isotope dilution technique. J Mass Spectrom. 2004; 39(11):1287-94. DOI: 10.1002/jms.684. View

18.

Schulze F, Wesemann R, Schwedhelm E, Sydow K, Albsmeier J, Cooke J . Determination of asymmetric dimethylarginine (ADMA) using a novel ELISA assay. Clin Chem Lab Med. 2004; 42(12):1377-83. DOI: 10.1515/CCLM.2004.257. View

19.

Vanholder R, Massy Z, Argiles A, Spasovski G, Verbeke F, Lameire N . Chronic kidney disease as cause of cardiovascular morbidity and mortality. Nephrol Dial Transplant. 2005; 20(6):1048-56. DOI: 10.1093/ndt/gfh813. View

20.

Fliser D, Kronenberg F, Kielstein J, Morath C, Bode-Boger S, Haller H . Asymmetric dimethylarginine and progression of chronic kidney disease: the mild to moderate kidney disease study. J Am Soc Nephrol. 2005; 16(8):2456-61. DOI: 10.1681/ASN.2005020179. View